ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the top gainers of the stock market today, skyrocketing 2.97% or (1.22 points) to $42.42 from its previous close of $41.2. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 526062 contracts so far this session. ACAD shares had a relatively better volume day versus average trading capacity of 2.06 million shares, but with a 0.15 billion float and a -2.85% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ACAD stock indicates that the average analyst price target is $53.64 per share. This means the stock has a potential increase of 26.45% from where the ACAD share price has been trading recently which is between $40.825 and $41.93. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $40. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $66.
During the recent trading session for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), the company witnessed their stock drop by $-0.49 over a week and surge $1.99 from the price 20 days ago. When compared to their established 52-week high of $44.85, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 09/16/19. The recent low of $14.01 stood for a -5.41% since 12/24/18, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.82 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for ACAD is set at $53.5, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for ACADIA Pharmaceuticals Inc., the two-week RSI stands at 56.4. This figure suggests that ACAD stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current ACAD readings is similarly very revealing as it has a stochastic reading of 43.65% at this stage. This figure means that ACAD share price today is being neutral.
Technical chart claims that ACADIA Pharmaceuticals Inc. (ACAD) would settle between $41.81/share to $42.42/share level. However, if the stock price goes below the $40.71 mark, then the market for ACADIA Pharmaceuticals Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $40.21 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.6. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Oppenheimer, assumed coverage of ACAD assigning Perform rating, according to their opinion released on October 24. RBC Capital Mkts, analysts launched coverage of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock with a Outperform recommendation, according to their flash note issued to investors on October 01. Analysts at SVB Leerink released an upgrade from Mkt Perform to Outperform for the stock, in a research note that dated back to September 13.
ACAD equity has an average rating of 2.64, with the figure leaning towards a bullish end. 12 analysts who tracked the company were contacted by Reuters. Amongst them, 3 rated the stock as a hold while the remaining 9 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 9 analysts rated ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
ACADIA Pharmaceuticals Inc. (ACAD)’s current-quarter revenues are projected to climb by nearly 62.1% to hit $96.57 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 50.7% from $223810 to a noteworthy $337370. At the other end of the current quarter income statement, ACADIA Pharmaceuticals Inc. is expected to see its adjusted earnings surge by roughly 28% to hit $-0.36 per share. For the fiscal year, ACAD’s earnings are projected to climb by roughly 16.5% to hit $-1.62 per share.